Application
Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis.
Biochem/physiol Actions
Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000.
Quality
Functionally active by a sensitive hemolytic assay.
Other Notes
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
- UPC:
- 41116127
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- C3160-.1MG
